Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Financing Activities (2016 - 2025)

Cardiff Oncology's Cash from Financing Activities history spans 14 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 94.22% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, down 95.2%, while the annual FY2025 figure was $2.6 million, 95.2% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.6 million at Cardiff Oncology, up from $25000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $44.2 million in Q4 2024 and bottomed at $3000.0 in Q1 2025.
  • The 4-year median for Cash from Financing Activities is $2.1 million (2024), against an average of $8.4 million.
  • The largest annual shift saw Cash from Financing Activities fell 15.57% in 2021 before it plummeted 99.66% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $15.0 million in 2021, then tumbled by 99.5% to $75000.0 in 2022, then surged by 58817.33% to $44.2 million in 2024, then tumbled by 94.22% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Cash from Financing Activities are $2.6 million (Q4 2025), $25000.0 (Q3 2025), and $3000.0 (Q1 2025).